The indication of a
chemotherapy is advisable with patients who are suffering from a progressively metastasised, secondarily
hormone refractory
carcinoma of the prostate. In search of efficient
chemotherapy protocols we combined
cisplatin with
epirubicin (PE scheme) in our clinic. Massive side effects of that aggressive
chemotherapy scheme like gastro-intestinal trouble and myelotoxicity are the limiting factors of the scheme. With measures like reducing the dosage, delaying the next cycle, or breaking off the
therapy the effective dosage can often not be achieved. The
anti-emetics which are usually used today exclusively give
anti-emetic protection. The additional administration of xenogenic
peptides (
Factor AF2) had additionally myeloprotective effect in former studies. In this study we examined whether, by additionally giving
Factor AF2, the patients' subjective condition, and above all their hemogram, could be stabilised in order to achieve the effective dosage or dosage intensity. For that, the patients were prospectively randomised in two groups by means of a random selection board. The analysis of the data gained in the protocol showed that the additional administration of
Factor AF2 improves the patients' subjective conditions significantly. Apart from that, we noticed a considerable reduction of the
vomiting frequency. Concerning the objective measured parameters of the leukocytes, thrombocytes, erythrocytes, and the
hemoglobin level, the significantly myeloprotective effect of
Factor AF2 could be proved. Due to the fact that in the verum group there were considerably fewer cases of breaking off or delays of the treatment than in the control group, the effective dosage intensity could be achieved with a higher number of patients in that group.